Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
 Gilead blocks HIV drug generics for more than 10 years
Americas
The pharma giant extends market exclusivity for a top-selling drug accounting for nearly half of its multi-billion-dollar sales.   9 October 2025
Bridging Brunel and AI: Why CIPA sees ‘a golden opportunity’
Europe
The promises and pitfalls of AI took centre stage at CIPA’s annual congress in Bristol this week, as Sarah Speight reports.   9 October 2025
Teva in-house counsel jumps to private practice
Careers
The hire brings experience managing global trademark, copyright, and domain portfolios, as well as prior in-house roles at Teva and Johnson & Johnson.   9 October 2025
Americas
A 2021 Supreme Court ruling changed how patent terms are calculated, forcing pharma companies to rethink their IP strategies. Juliana Neves of Licks explains the key changes, upcoming reforms, and how companies can protect their portfolios effectively.   8 October 2025
Americas
The pharma giant will share rights to new innovations with an AI-driven organoid platform designed to produce fully human antibodies in weeks.   7 October 2025
Big Pharma
Can AI tools raise the bar for inventiveness? And when algorithms become as productive as living systems, will they make their own outputs unpatentable? Industry experts unpick AI drug discovery’s biggest issues.   6 October 2025
Careers
The new recruits, who join the firm’s LA and NYC offices, bring specialisms in technology, commerce, pharma, agriculture and biotechnology.   6 October 2025
Careers
Life sciences specialist boosts its London office with an expert in small molecules, biologics, and gene therapy before UK courts, the UPC, and the EPO.   3 October 2025
Americas
A spike in agency investigations and more female lead counsel still leave a notable gender gap at the venue, find Troutman Pepper Locke’s Emma Mann, Gwendolyn Tawresey, Brittany Reeves, and Gillian Schutt.   3 October 2025
Americas
From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze.   2 October 2025